IL17A and cancer: Nonetheless, IL-17-producing γδ-T cells have been exceptionally hard to find in humans [20,40] and their potential to mount immune responses, independent of MHC-activation, make γδ-T cells attractive targets for “off-the-shelf” immunotherapy for breast and other cancers.